RxDoctor Payments Data

Jose Baez, DO

Internal Medicine · Lawrence, MANPI 1336103233

Payments from drug & device makers

$31,729in general payments, 2019–2025

Across 1,634 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • AbbVie$6K
  • Novo Nordisk$2K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • plus $15K from 54 others

What the payments were for

  • Food & beverage$31,45299%
  • Education$2771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca246$5,655
AbbVie(2 entities)336$5,572
Novo Nordisk92$1,598
GSK90$1,442
Lilly USA, LLC80$1,355
Boehringer Ingelheim51$1,337
Amgen65$1,326
Astellas Pharma US Inc44$1,205
Merck56$1,132
Pfizer73$1,129
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC63$1,097
Johnson & Johnson38$756
Novartis38$713
Bayer27$554
Amarin Pharma, Inc.36$538
Sumitomo Pharma America, Inc.22$520
Phathom Pharmaceuticals, Inc.19$418
E.r. Squibb & Sons, L.L.C.17$339
Ironwood Pharmaceuticals, Inc16$327
Takeda Pharmaceuticals U.S.A., Inc.19$318
Corcept Therapeutics9$307
Biohaven Pharmaceuticals, Inc.13$296
Lundbeck LLC18$291
Sanofi3$281
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$265
Qiagen, LLC3$257
Esperion Therapeutics, Inc.13$253
Teva Pharmaceuticals USA, Inc.34$218
Otsuka America Pharmaceutical, Inc.11$217
Eisai Inc.14$213
Biohaven Pharmaceutical Holding Company Ltd.10$207
Galderma Laboratories, L.p.1$133
Redhill Biopharma Inc.6$110
Exact Sciences5$107
Ardelyx, Inc.5$104
Abiomed1$84
Xeris Pharmaceuticals, Inc.4$84
Dexcom, Inc.2$76
Sanofi-aventis U.S. LLC3$71
Regeneron Healthcare Solutions, Inc.3$69
Aimmune Therapeutics, Inc.3$68
Lexicon Pharmaceuticals, Inc.3$56
Mylan Specialty L.p.3$56
Abbott3$55
Scpharmaceuticals Inc.2$52
QOL Medical, LLC2$45
Upsher-smith Laboratories LLC2$44
Nestle Healthcare Nutrition Inc.3$41
Viatris Specialty LLC2$41
Shield Therapeutics Inc2$41
Hologic Sales And Service, LLC2$38
Kowa Pharmaceuticals America, Inc.2$33
Idorsia Pharmaceuticals US Inc1$23
Medtronic1$22
Genentech USA, Inc.1$21
Radius Health, Inc.1$18
Mannkind Corporation1$16
Biogen1$15
Cequr Corporation1$15
Hikma Pharmaceuticals USA1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,729 in reported general payments places this provider in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$141,120
Medicare patients
202
Services billed
2,591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol1,472$947,742
TrulicityDulaglutide683$696,058
JanuviaSitagliptin Phosphate825$508,676
LinzessLinaclotide550$335,308
MyrbetriqMirabegron509$243,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter332$221,899
OzempicSemaglutide135$159,385
EliquisApixaban247$159,312
Breztri AerosphereBudesonide/Glycopyr/Formoterol244$156,597
JardianceEmpagliflozin167$123,315
CreonLipase/Protease/Amylase68$97,052
BiktarvyBictegrav/Emtricit/Tenofov Ala23$91,153
EntrestoSacubitril/Valsartan127$87,406
MounjaroTirzepatide74$79,147
TradjentaLinagliptin118$68,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$5,655$1,163,6011,837 claims
Lilly USA, LLCTrulicity, Mounjaro$1,355$775,205757 claims
MerckJanuvia$1,132$508,676825 claims
AbbVieLinzess, Creon$5,572$432,361618 claims
GSKTrelegy Ellipta, Arexvy, Anoro Ellipta$1,442$253,889417 claims
Astellas Pharma US IncMyrbetriq$1,205$243,945509 claims
Boehringer IngelheimJardiance, Tradjenta$1,337$191,431285 claims
Novo NordiskOzempic$1,598$159,385135 claims
PfizerEliquis$1,129$159,312247 claims
NovartisEntresto$713$87,406127 claims
Johnson & JohnsonXarelto$756$61,94498 claims
Sumitomo Pharma America, Inc.Gemtesa$520$39,11062 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Lawrence

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →